



# Annual Public Meeting of the Board of Directors

Hybrid Event | July 21, 2026

2:30pm (eastern)

## Agenda

| Time   | Session                                                                                                                                                                                                                                                                                                                                                             |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2:30pm | <b>Welcome &amp; Call to Order</b> <ul style="list-style-type: none"><li>• <b>Adrian F. Hernandez, MD, MHS</b><br/>Board Chair, Reagan-Udall Foundation for the FDA</li></ul>                                                                                                                                                                                       |
|        | <b>Year in Review</b> <ul style="list-style-type: none"><li>• <b>Adrian F. Hernandez, MD, MHS</b></li><li>• <b>Susan C. Winckler, RPh, Esq.</b><br/>Chief Executive Officer, Reagan-Udall Foundation for the FDA</li></ul>                                                                                                                                          |
|        | <b>The Year Ahead: Strategic &amp; Scientific Priorities</b> <ul style="list-style-type: none"><li>• <b>Steven Kozlowski, MD</b><br/>Chief Scientist, U.S. Food and Drug Administration</li><li>• <b>Lowell Zeta, JD</b><br/>Acting Chief of Staff, Deputy Commissioner for Strategic Initiatives, and Special Counsel, U.S. Food and Drug Administration</li></ul> |
|        | <b>Exploring the Foundation's Impact</b><br>A discussion with members of the Foundation's Board of Directors <ul style="list-style-type: none"><li>• <b>David C. Fajgenbaum, MD, MBA, MSc, FCPP</b></li><li>• <b>Adrian F. Hernandez, MD, MHS</b></li><li>• <b>Phuong Khanh (PK) Morrow, MD</b></li><li>• <b>Pietro Antonio Tataranni, MD</b></li></ul>             |
|        | <b>Remarks from the Acting Commissioner</b> <ul style="list-style-type: none"><li>• <b>Kyle Diamantas, JD</b><br/>Acting Commissioner of Food and Drugs<br/>U.S. Food and Drug Administration</li></ul>                                                                                                                                                             |
|        | <b>Closing Remarks &amp; Adjourn</b> <ul style="list-style-type: none"><li>• <b>Winckler</b></li></ul>                                                                                                                                                                                                                                                              |